February MIMS Update

Some of the recent changes to the medicines landscape, with new products, presentations, indications and contraindications New products Delgocitinib (Anzupgo) is a pan Janus kinase (JAK) inhibitor that targets the activity of all four members of the JAK family of enzymes consisting of JAK1, JAK2, JAK3, and tyrosine kinase 2 in a concentration dependent manner.